Skip to main content

Myelofibrosis (MF) is myeloproliferative tumor (MPN), which can manifest as primary myelofibrosis (PMF) or secondary MF developed from other MPN, including post polycythemia vera myelofibrosis (post-PV MF) and post-essential thrombocytosis (post ET-MF).

Revive Research Institute is conducting a new study on an investigational drug to better treat patients with malignant myeloid hematologic neoplasms. The two-phase study will assess antitumor effect, safety, and tolerability of the investigational drug in patients with relapsed/refractory acute myeloid leukemia (AML) without standard therapy, or other relapsed/refractory malignant myeloid hematologic neoplasms without standard therapy such as PMF, post-PV MF, or post-ET MF.

Participation Criteria:

  • Adults 18 years of age or older, male or female
  • Confirmed diagnosis of PMF, post-PV MF, or post-ET MF which failed to standard treatment
  • Must have symptomatic splenomegaly
  • Must not have undergone a splenectomy or splenic radiation therapy within 6 months prior to screening

Our group of licensed and certified physicians will be keeping track of the patient’s progress throughout the study and will address any concerns or queries that arise regarding the research trial. The investigational treatment is free for the duration of the clinical trial and insurance is not required. All patient records and information will be kept secure and confidential. The patient will also receive compensation for their time and involvement.

Please provide YOUR contact information only.

If you require any further information, feel free to contact us at 248-564-1485.

Close Menu

Revive Research Institute, Inc.

28270 Franklin Road
Southfield, MI

T: 248-564-1485